Stock Screener App

Gratuito -

Installare

0.432

4.66% -0.0211

after-market

Dopo l'orario di chiusura: .43 -0.002 -0.46%

Neurosense Therapeutics Ltd (NRSN)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie

Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us

Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com

NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - TipRanks

NeuroSense Issues CEO Letter to Shareholders - PR Newswire

NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et

Global Neurodegenerative Disease Market is Expected to - GlobeNewswire

NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks

Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - Nasdaq

NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan

NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split - TipRanks

NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock Titan

NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan - Stock Titan

Neurosense Therapeutics is a buy, this analyst says - Cantech Letter

Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView

Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z - TradingView

Neurosense Therapeutics Ltd - TradingKey

Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey

NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey

Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey

NRSN|Neurosense Therapeutics Ltd|Price:0.500|Chg%:-0.003 - TradingKey

TradingKey - TradingKey

NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks

NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire

NeuroSense Therapeutics (NRSN) Faces Headwinds: Stock Retreats 5.6% to $0.69 Amid Sector PressureOBV Divergence - dars.gov.et

NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66Calendar Spread Trade - dars.gov.et

NeuroSense Therapeutics (NRSN) Edges Higher as Key Support HoldsEquity Put Call - dars.gov.et

NeuroSense Therapeutics Ltd. (NRSN) Latest Stock News & Headlines - Yahoo Finance

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - Nasdaq

Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView

Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView

NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings - TradingView

NeuroSense bolsters case for multi-target Alzheimer’s strategy - Longevity.Technology

NRSN Q2 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineBasic EPS Analysis - dars.gov.et

NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS - Bakersfield.com

NeuroSense (NRSN) Achieves Key Milestone in ALS Study - GuruFocus

NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3 - TipRanks

NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint - marketscreener.com

NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3 - Stock Titan

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - Nasdaq

NeuroSense reports positive Phase 2b ALS data - grafa.com

NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease - BioSpectrum Asia

Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN) - TradingView

Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

NRSN Forecast — Price Target — Prediction for 2027 - TradingView

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD - GuruFocus

Price to book forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Number of shareholders of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView

NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial - TipRanks

NeuroSense (NRSN) reports early Phase 2 PrimeC biomarker signals in Alzheimer’s - Stock Titan

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease - PR Newswire

Enterprise value to EBITDA forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Number of shareholders of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Price to sales forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Enterprise value to EBIT forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

EverythingALS to Host NeuroSense in a Community Event Named: PrimeCConnecting the Dots - The AI Journal

EverythingALS to Host NeuroSense in a Community Event Named: Pri - GuruFocus

NRSN Q2 2025 Earnings: Narrower Loss Per Share Beats Estimates, Stock SurgesBuyback Announcement Report - po-news-eg.net

NRSN Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView

MRNA

$64.46

1.80%

ROIV

$36.24

0.11%

RPRX

$59.45

1.45%

INSM

$128.32

3.70%

ALNY

$224.60

1.77%

ONC

$362.51

4.33%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters